[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602005026290D1 - Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren - Google Patents

Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren

Info

Publication number
DE602005026290D1
DE602005026290D1 DE602005026290T DE602005026290T DE602005026290D1 DE 602005026290 D1 DE602005026290 D1 DE 602005026290D1 DE 602005026290 T DE602005026290 T DE 602005026290T DE 602005026290 T DE602005026290 T DE 602005026290T DE 602005026290 D1 DE602005026290 D1 DE 602005026290D1
Authority
DE
Germany
Prior art keywords
compositions
progesterone receptor
delayed release
receptor modulators
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005026290T
Other languages
English (en)
Inventor
Regine Sitruk-Ware
Yun-Yen Tsong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire HRA Pharma SAS
Population Council Inc
Original Assignee
Laboratoire HRA Pharma SAS
Population Council Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire HRA Pharma SAS, Population Council Inc filed Critical Laboratoire HRA Pharma SAS
Publication of DE602005026290D1 publication Critical patent/DE602005026290D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
DE602005026290T 2004-07-09 2005-07-08 Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren Active DE602005026290D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58678304P 2004-07-09 2004-07-09
PCT/US2005/024474 WO2006010097A2 (en) 2004-07-09 2005-07-08 Sustained release compositions containing progesterone receptor modulators

Publications (1)

Publication Number Publication Date
DE602005026290D1 true DE602005026290D1 (de) 2011-03-24

Family

ID=35785781

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005026290T Active DE602005026290D1 (de) 2004-07-09 2005-07-08 Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren

Country Status (16)

Country Link
US (1) US8865200B2 (de)
EP (1) EP1768625B1 (de)
JP (2) JP5017109B2 (de)
KR (1) KR101229701B1 (de)
CN (1) CN101080205B (de)
AT (1) ATE497745T1 (de)
AU (1) AU2005265357B2 (de)
BR (1) BRPI0513141A (de)
CA (1) CA2573266C (de)
DE (1) DE602005026290D1 (de)
DK (1) DK1768625T3 (de)
ES (1) ES2360806T3 (de)
MX (1) MX2007000273A (de)
NZ (1) NZ552720A (de)
PT (1) PT1768625E (de)
WO (1) WO2006010097A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436428B1 (en) * 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
GB0222522D0 (en) * 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US8399013B2 (en) 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
US8404272B2 (en) 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US8062658B2 (en) * 2004-12-14 2011-11-22 Poly-Med, Inc. Multicomponent bioactive intravaginal ring
EP1862468A1 (de) 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
GB0613333D0 (en) * 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) * 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
BRPI0713203A2 (pt) * 2006-07-12 2012-04-03 Controlled Therapeutics Scotland Ltda inserto, métodos, embalagem, dispositivo recuperável e dispositivo inserìvel
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
TWI455716B (zh) * 2006-10-24 2014-10-11 Repros Therapeutics Inc 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途
ES2814343T3 (es) 2006-10-24 2021-03-26 Allergan Pharmaceuticals Int Ltd Composiciones y métodos para suprimir las proliferaciones endometriales
EP2148681B1 (de) * 2007-04-20 2016-03-16 PregLem S.A. Selektive progesteronmodulatoren zur behandlung von uteriner blutung
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
AU2009210779B2 (en) 2008-02-04 2015-04-02 Ferring B.V. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
US9034365B2 (en) 2008-05-20 2015-05-19 Poly-Med, Inc. Biostable, multipurpose, microbicidal intravaginal devices
EP3106167A1 (de) 2009-04-14 2016-12-21 Laboratoire HRA Pharma Verfahren zur bedarfsabhängigen kontrazeption
EP2419109B1 (de) 2009-04-14 2016-04-13 Laboratoire HRA-Pharma Verfahren zur bedarfsweisen kontrazeption mit levonorgestrel oder norgestrel
US20120070476A1 (en) * 2009-05-29 2012-03-22 Moench Thomas R Compositions and Methods for Inactivation of Pathogens at Genital Tract Surfaces
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
MX2012010327A (es) * 2010-03-22 2012-11-16 Repros Therapeutics Inc Composiciones y metodos para la administracion no toxica de antiprogestinas.
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE202011110355U1 (de) * 2011-03-09 2014-01-15 Arstat, Inc. Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes
EP2545922A1 (de) 2011-07-12 2013-01-16 PregLem S.A. Behandlung von übermäßiger Monatsblutung im Zusammenhang mit Gebärmutterfibromen
IL215224A0 (en) * 2011-09-18 2012-02-29 Katz Daniel Dr Vaginal danazol combined with non steroidal anti inflammatory drugs (nsaids) compositions
MX354579B (es) * 2011-12-29 2018-03-12 Laboratorios Andromaco S A Ex Inversiones Gruchi S A Anillo vaginal que comprende meloxicam y un agente modulador de la liberacion del principio activo, util como anticonceptivo de uso continuo en mujeres.
FR2987271B1 (fr) * 2012-02-28 2017-08-18 Hra Pharma Lab Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens
EP2641602A1 (de) 2012-03-23 2013-09-25 PregLem S.A. Verfahren zur Behandlung gynäkologischer Leiden
SG11201407397WA (en) 2012-05-31 2014-12-30 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
WO2014050105A1 (en) * 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Amorphous ulipristal acetate
AU2013338305B2 (en) 2012-11-02 2018-06-07 Allergan pharmaceuticals International Ltd. Methods and compositions for treating progesterone-dependent conditions
FR2997627B1 (fr) 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
FR2997628B1 (fr) 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
FR2999081B1 (fr) 2012-12-06 2015-02-27 Hra Pharma Lab Dispersion solide d'un modulateur selectif du recepteur a la progesterone
JP6249790B2 (ja) 2013-01-29 2017-12-20 三菱鉛筆株式会社 シャープペンシル
CA2907674A1 (en) 2013-04-10 2014-10-16 Preglem Sa Progesteron receptor modulators for use in the therapy of uterine fibroids
JP6486900B2 (ja) 2013-04-11 2019-03-20 バイエル・ファルマ・アクティエンゲゼルシャフト プロゲステロン受容体アンタゴニスト剤形
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
DE102014004388A1 (de) * 2014-03-26 2015-10-01 Angela Kayser Verfahren und System zum intravaginalen Verabreichen von Progesteron
US20170020718A1 (en) * 2014-04-01 2017-01-26 Poly-Med, Inc. Contraceptive and related device
SI2982352T1 (sl) 2014-06-28 2018-12-31 Laboratorios Andromaco S.A. Cervikalni pesar, ki vsebuje progesteron za podaljšano, zakasnjeno in kontinuirano sproščanje, ki se uporablja za preprečevanje prezgodnjega poroda
KR20170084086A (ko) 2014-11-17 2017-07-19 아르노 테라퓨틱스 인코포레이티드 오나프리스톤 연장-방출 조성물 및 방법
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
AU2016370499B2 (en) * 2015-12-15 2022-06-30 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
CN114073792A (zh) * 2020-08-11 2022-02-22 上海市生物医药技术研究院 含来曲唑的阴道环、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) * 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3948254A (en) * 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
AU710139B2 (en) * 1996-05-01 1999-09-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The 21-substituted progesterone derivatives as new antiprogestational agents
US5972372A (en) * 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
US6358947B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
FR2822022B1 (fr) 2001-03-19 2005-11-04 Atofina Traitement pesticide des sols agricoles avec des composes soufres
CN1210079C (zh) * 2001-04-25 2005-07-13 上海市计划生育科学研究所 阴道环制剂及其应用
EP1620060B1 (de) 2003-04-29 2010-03-24 The General Hospital Corporation Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits

Also Published As

Publication number Publication date
DK1768625T3 (da) 2011-05-09
US8865200B2 (en) 2014-10-21
AU2005265357A1 (en) 2006-01-26
CN101080205B (zh) 2011-10-12
WO2006010097A3 (en) 2006-08-10
EP1768625A2 (de) 2007-04-04
CA2573266C (en) 2011-11-08
BRPI0513141A (pt) 2008-04-29
ATE497745T1 (de) 2011-02-15
US20080199511A1 (en) 2008-08-21
KR20070044005A (ko) 2007-04-26
CA2573266A1 (en) 2006-01-26
JP2012040400A (ja) 2012-03-01
MX2007000273A (es) 2007-05-21
EP1768625A4 (de) 2008-07-09
JP5017109B2 (ja) 2012-09-05
WO2006010097A2 (en) 2006-01-26
CN101080205A (zh) 2007-11-28
PT1768625E (pt) 2011-04-18
JP2008505718A (ja) 2008-02-28
NZ552720A (en) 2010-02-26
AU2005265357B2 (en) 2011-04-07
KR101229701B1 (ko) 2013-02-05
EP1768625B1 (de) 2011-02-09
ES2360806T3 (es) 2011-06-09

Similar Documents

Publication Publication Date Title
DE602005026290D1 (de) Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
ECSP077131A (es) Regímenes y los juegos de anticonceptivos del antagonista del receptor de progesterona
MX2010012397A (es) Composiciones de corticosteroides de liberacion controlada y metodos para el tratamiento de transtornos oticos.
WO2011049958A3 (en) Modulation of gel temperature of poloxamer-containing formulations
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
ECSP077233A (es) Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos
MX339797B (es) Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
RS20070076A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
EA201291372A1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
PL1989218T3 (pl) Pochodne 17-fosforosteroidów użyteczne jako modulatory receptora progesteronowego
MY142850A (en) Novel indole derivatives as selective androgen receptor modulators (sarms)
MD4591B1 (ro) Dispersie solidă a unui modulator selectiv al receptorului de progesteron
WO2006066011A3 (en) Compounds and compositions as modulators of steroidal receptors and calcium channel activities
ATE347358T1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
WO2007098381A3 (en) 11-phosphorous steroid derivatives useful as progesterone receptor modulators
TW200604171A (en) Novel indole derivatives as selective androgen receptor modulators (SARMs)
TW200604170A (en) Novel indole derivatives as selective androgen receptor modulators (SARMs)
WO2009076413A3 (en) Methods, devices and compositions for controlled drug delivery to injured myocardium
UA92500C2 (ru) Цианопирролсульфонамидные модуляторы прогестеронового рецептора и их применение
EA200702604A1 (ru) Производные бензофуранона как нестероидные модуляторы рецептора прогестерона
EA200970376A1 (ru) Peg-илированный паратиреоидный гормон в качестве модулятора рецептора паратиреоидного гормона и его применение
DK1732921T3 (da) Thiomidderivater som progesteronreceptormodulatorer